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Abstract
Background: The use of antibiotics during pregnancy is associated with increased aller-
gic asthma risk in the offspring, and given that approximately 25% of pregnant women 
are prescribed antibiotics, it is important to understand the mechanisms contributing 
to this phenomenon. Currently, there are no studies that directly test this association 
experimentally. Our objective was to develop a mouse model in which antibiotic treat-
ment during pregnancy results in increased offspring asthma susceptibility.
Methods: Pregnant mice were treated daily from gestation day 8-17 with an oral so-
lution of the antibiotic vancomycin, and three concentrations were tested. At wean-
ing, offspring were subjected to an adjuvant-free experimental asthma protocol using 
ovalbumin as an allergen. The composition of the gut microbiome was determined in 
mothers and offspring with samples collected from five different time points; short-
chain fatty acids were also analyzed in allergic offspring.
Results: We found that maternal antibiotic treatment during pregnancy was associated 
with increased offspring asthma severity in a dose-dependent manner. Furthermore, 
maternal vancomycin treatment during pregnancy caused marked changes in the gut 
microbiome composition in both mothers and pups at several different time points. 
The increased asthma severity and intestinal microbiome changes in pups were also 
associated with significantly decreased cecal short-chain fatty acid concentrations.
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1  | INTRODUC TION
Allergic asthma constitutes a morbidity of increasing prevalence and 
is the leading cause of chronic disease in children. During asthma 
exacerbation, inflammation of the respiratory epithelia manifests as 
airway hyperreactivity and breathing difficulties that can substan-
tially reduce quality of life. Though it is not completely clear how 
atopy initially arises, it is commonly accepted that allergic asthma 
results from a failure to generate protective immunologic tolerance 
against particular aeroallergens. Pursuing this further, several lines 
of evidence suggest that the ability to generate tolerance is devel-
oped during the fetal and neonatal life stages.1 The “Developmental 
Origins Hypothesis” proposes that environmental influences during 
these critical time points can alter disease susceptibility in early life.2
There is considerable evidence that the use of antibiotics during 
pregnancy contributes to increased asthma susceptibility in chil-
dren.3-6 During birth, the maternal vaginal, perineal, and fecal mi-
crobiome seed the initial intestinal colonization of the newborn.7,8 
Consequently, antibiotics taken during pregnancy have been shown 
to alter both the maternal and neonatal microbiomes in humans,9 
rats,10 and mice.11 The early life microbiome is crucial for the proper 
development of immune system functions, whereas microbial dysbi-
osis in early life is associated with altered neonatal immunity 11 and 
is thought to bias the maturing neonatal immune system toward a 
hypersensitive state.2,12 Considering allergic airway diseases, stud-
ies demonstrate that germ-free mice displayed increased asthma 
severity compared to mice with a conventional commensal micro-
biome.13 It was also shown that rescue of the severe asthma pheno-
type in germ-free mice was only possible by supplementation with 
commensal microbes during early life, but not in adulthood.14 The 
neonatal microbiome is therefore critical for establishing immunity 
and mucosal tolerance.
In addition to contributing to immune system development in 
early life, intestinal microbes also facilitate the digestion of dietary 
fiber, resulting in the production of short-chain fatty acids (SCFAs). 
Acetate, propionate, and butyrate are the major metabolic by-prod-
ucts of bacterial fiber fermentation, and these SCFAs are associated 
with asthma susceptibility. Longitudinal human studies revealed that 
Conclusion: Consistent with the “Developmental Origins Hypothesis,” our results 
confirm that exposure to antibiotics during pregnancy shapes the neonatal intestinal 
environment and increases offspring allergic lung inflammation.
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G R A P H I C A L  A B S T R A C T
We found that maternal antibiotic treatment during pregnancy was associated with increased offspring asthma severity in a dose dependent 
manner. Maternal vancomycin treatment during pregnancy caused marked changes in the gut microbiome composition in both mothers and 
pups at several different time points. The increased asthma severity and intestinal microbiome changes in pups were also associated with 
significantly decreased cecal short chain fatty acid concentrations.
Abbreviations: BAL, bronchoalveolar lavage; OVA, ovalbumin; SCFAs, short chain fatty acids.
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increased levels of fecal butyrate and propionate in the first year 
of life were significantly associated with protection from asthma at 
6 years of age,15 whereas decreased fecal acetate concentrations at 
3 months of age were associated with asthma diagnosis at 3 years 
of age.16 Studies in mice showed that increased fecal SCFAs were 
associated with protection against airway inflammation,17 whereas 
decreased SCFA concentrations were associated with more severe 
allergic airway diseases.18 Direct supplementation of adult mice with 
SCFAs17,19,20 also effectively protected from airway inflammation.
Antibiotics account for 80% of prescriptions given during preg-
nancy.21 Given the strong association between maternal antibiotic 
use and offspring asthma susceptibility, it is increasingly important 
to understand the mechanisms behind this phenomenon. There are, 
however, no experimental in vivo models available to date that ex-
amine the effect of antibiotics given only during pregnancy on 
offspring asthma. In the present study, we therefore established a 
mouse model in which maternal exposure to vancomycin resulted in 
increased asthma severity in the offspring.
2  | METHODS
2.1 | Animals
Twelve-week-old female BALB/c mice were obtained from Janvier 
Labs (Le Genest-Saint-Isle). Mice were kept under specific pathogen-
free conditions and housed five animals per cage in a 12/12 hours 
light/dark cycle. Food and water were available ad libitum. All ani-
mal experiments were approved by local authorities (Landesamt für 
Gesundheit und Soziales; LAGeSo; registration number: G0158/18) 
and were performed in accordance with German and international 
guidelines.
2.2 | Experimental design
The presence of a vaginal plug after male and female co-habi-
tation was denoted as gestation day (G)0. From G8 to G17, preg-
nant mice received a daily oral dose of the antibiotic vancomycin 
(Sigma-Aldrich) corresponding to 10, 20 or 40 mg/kg body weight. 
Vancomycin was specifically chosen because it is poorly absorb-
able, limiting the possibility that the antibiotic will directly affect the 
developing fetus, and allowing investigation of the downstream ef-
fects of maternal vancomycin use during pregnancy. Pregnant mice 
were given the antibiotic mixture (25 µL of vancomycin +15 µL Ora-
Sweet syrup; Paddock Laboratories) through drops from a pipet; 
control animals were sham treated with water + syrup (Figure 1A, 
B). To reduce human error, we used a calibrated micropipette to ad-
minister this volume orally to each individual mouse. To ensure that 
the entirety of the volume was consumed, we visually confirmed 
after drug administration that each mouse had finished swallowing 
(5-10 seconds) before returning the animal to the cage (Figure 1C). 
Female offspring were weaned at 21 days of age, and experimental 
asthma was induced by subcutaneous sensitization using 10 µg oval-
bumin (OVA VI—Sigma) in 200 µL PBS, once per week for 3 weeks. 
The asthma phenotype was induced by exposing the offspring for 
20 minutes daily to a 1% OVA aerosol (OVA V—Sigma) for 3 days 
(Figure 1A, B). Twenty-four hours after the last OVA challenge, the 
asthma phenotype was assessed.22
2.3 | Molecular analysis of maternal and offspring 
fecal microbiomes
2.3.1 | 16S rRNA qPCR
Fresh fecal pellets were immediately frozen and stored at −80°C. 
Maternal fecal samples were collected 14 days before mating, at G17, 
and at weaning. Offspring feces were collected at weaning (21 days of 
age) and after allergic asthma exacerbation (7 weeks of age). Fecal DNA 
was extracted and then quantified using Quant-iT PicoGreen reagent 
(Invitrogen) as described in.23 qPCR was chosen to obtain a broad sur-
vey of the bacterial groups present, as well as to determine how mater-
nal vancomycin treatment influenced the quantity of bacteria present 
in mothers and offspring. Briefly, numbers of 16S rRNA gene copies 
per ng DNA were quantified in each sample using species-, genera- or 
group-specific primers (TIB MOLBIOL) assessed by qRT-PCR. Primer 
sequences can be found in Table S1.24 Total bacteria load was assessed, 
as well as the following bacterial groups: Gammaproteobacteria/
Enterobacteriaceae (Enterobacteriaceae), Bacteroides/Prevotella/
Porphyromonas (Bacteroidetes), Mouse Intestinal Bacteroides, 
Clostridium leptum, Clostridium coccoides/Eubacterium rectale, 
Enterococcus, Lactobacillus, and Bifidobacterium.
2.3.2 | 16S rRNA sequencing
DNA was extracted using the PowerSoil for KingFisher kit (MO Bio) 
following manufacturer's instructions. 16S rRNA V4 gene fragments 
were amplified using bar-coded primers as described in 25 with the 
following primer regions (5′-3′): fwd: GTGCCAGCMGCCGCGGTAA, 
rev: GGACTACHVGGGTWTCTAAT. Pooled PCR amplicons were 
diluted to 20 ng/mL and sequenced using MiSeq 2000 bi-direc-
tional Illumina sequencing and Cluster Kit v4 (Macrogen). Library 
preparation was done using TruSeq DNA Sample Prep v2 Kit 
(Illumina) with 100 ng of DNA per sample. The library was quan-
tified and quality-checked using Qubit (Thermo Fisher Scientific). 
DNA extraction, amplification, and sequencing were performed 
by Microbiome Insights Inc. Sequence data were trimmed, quality-
filtered, and clustered at 97% identity into operational taxonomic 
units (OTUs) using a modified MOTHUR standard operating pro-
cedure.26 An average of 31 554 quality-filtered reads were gener-
ated per sample, and there was a total of 8631 OTUs. The OTUs 
were taxonomically annotated using the SILVA database.27 Global 
community structure comparisons were made in an R environment 
using Phyloseq.28
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2.4 | Blood collection and antibody measurements
Blood samples were taken from the orbital sinus of terminally 
anaesthetized mice and serum was stored at −80°C. Total IgG, OVA-
specific IgE and OVA-specific IgG1 were measured in the serum of 
OVA allergic offspring by an enzyme-linked immunosorbent assay 
(ELISA) (BD Bioscience).
2.5 | Bronchoalveolar lavage, cytospins, and 
bronchoalveolar lavage cytokine measurements
Using a tracheal cannula on euthanized offspring, Bronchoalveolar 
lavage (BAL) was performed once using 1 mL of 1× Complete Protease 
Inhibitor Cocktail (Roche). BAL supernatant was stored at –80°C, 
total leukocytes were counted with a Neubauer chamber, and cyto-
spin preparations were made and stained with Diff-Quick (Merz & 
Dade). Two hundred cells were counted per cytospin by a researcher 
blinded to the sample names. For BAL cytokine measurements, IL-1α, 
IL-1β, IL2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, 
IL-17A, Eotaxin, G-CSF, GM-CSF, IFNγ, KC, MCP-1, MIP-1α, MIP-1 β, 
RANTES, and TNF were measured using a mouse 23-plex cytokine 
assay (Bio-Rad), according to manufacturer's instructions.
2.6 | Lung collection and histology
Immediately after BAL, lungs were fixed with 4% formalin. 4 µm pe-
riodic acid-Schiff (PAS)-stained lung sections were microscopically 
analyzed using the new Computer Assisted Stereological Toolbox 
F I G U R E  1   The effect of antibiotic use during pregnancy on asthma development in the offspring—Mouse model description and 
pregnancy effects. A, Pregnant mothers were treated daily from G8-G17 with an oral dose of 10, 20 or 40 mg/kg vancomycin plus Ora-Sweet 
syrup. Control mothers were treated orally with water and Ora-Sweet. At weaning, all offspring were subjected to an experimental asthma 
protocol with a subcutaneous sensitization to ovalbumin (OVA) at 21, 28, and 35 days of age, and asthma provocation by a 20 min daily 
aerosol challenge at 46, 47, and 48 days of age. B, Overview of the treatment for each group. C, Oral administration of vancomycin plus Ora-
Sweet. The mouse is scruffed and presented the antibiotic via pipet, allowing the animal to voluntarily consume the drug-Ora-Sweet mixture. 
Untrained mice immediately learn this procedure and consume the entire mixture within 5-10 s of presentation. D, Litter size—Total offspring 
(entire bar), females (black bar) and males (white bar) born to mothers in each group. E, Weight of 7-wk-old allergic offspring that were 
prenatally exposed to maternal control or vancomycin during pregnancy. Data information: Means ± SEM are shown, control (n = 18), prenatal 
10 mg/kg (n = 19), prenatal 20 mg/kg (n = 18), prenatal 40 mg/kg (n = 16). Results represent two independently performed experiments. 
Significance is represented by **P < .01, one-way ANOVA with Dunnett's multiple comparisons test (10, 20, and 40 compared against control)
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1 (Control) 0 mg/kg (MC) OVA
2 10 mg/kg (MV10) OVA
3 20 mg/kg (MV20) OVA
4 40 mg/kg (MV40) OVA
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(newCAST; Visiopharm) as described in,29 by readers blinded to the 
study groups. For inflammation and goblet cell measurements, the 
software randomly selected 100 frames across multiple lung sec-
tions (40× objective), superimposed by a line grid and points. Point 
intercepts on an eosinophil or goblet cell were considered as a point 
of inflammation (PI) or point of goblet cell (PG), respectively. Line 
interceptions with the bronchial epithelium were considered a line of 
a goblet cell (LG) or line of a nongoblet cell (LnG), respectively. Line 
intercepts with blood vessel walls were labeled as line blood vessel 
(LV). Volume of inflammation (Vol. Inf), number of goblet cells (Nu. 
G), and volume of goblet cells (Vol. G) were calculated as follows:
2.7 | Analysis of SCFA from allergic offspring cecum
Cecal acetate, propionate, butyrate, and valerate were measured 
with an HP 5890 series II gas chromatograph (Hewlett-Packard) 
equipped with an HP-20 M column and a flame ionization detec-
tor. Previously, flash-frozen cecal contents from allergic offspring 
were diluted and centrifuged, then the supernatant was mixed with 
2-ethylbutyric acid as an internal standard, 0.36 M HClO4 and 1 M 
NaOH. The mixture was lyophilized overnight, and the remnant was 
re-dissolved in a mixture of 400 µL of acetone and 5 M formic acid. 
After centrifugation, 1 mL of the supernatant was injected into the 
gas chromatograph.
2.8 | Statistical analysis
Samples were tested for normal distribution using a Shapiro-Wilk 
normality test. Parametric/nonparametric data were analyzed by 
one-way ANOVA/Kruskal-Wallis (with Dunnett's multiple com-
parison test) or Mann-Whitney U test in the case of two groups. 
Calculations were performed with GraphPad Prism 7 software. To 
confirm the robustness of the statistics with respect to outliers, we 
performed an outlier analysis for every model with Cook's distance 
using base R. In the presence of outliers, the initial analyses were 
repeated after extracting the respective values from the dataset. 
These results confirmed our initial analyses. Additionally, all mod-
els were estimated with robust ANOVA’s using the WRS2 Package 
(version 0.10). Again, the analyses showed only small and expected 
differences to the initial analyses. Hence, we retained the initial re-
sults from the one-way ANOVA and Kruskal-Wallis tests. Pearson's 
correlation analysis and statistics were performed using the R pack-
age psych (version 1.8.12). Correlation figures were generated using 
ggplot230 and ColorBrewer (https://CRAN.R-proje ct.org/packa 
ge=RColo rBrewer). Multiple comparisons were corrected using the 
Benjamini-Hochberg method.
3  | RESULTS
3.1 | Model description
To examine the effect of antibiotics taken during pregnancy on the 
development of offspring asthma, we established a mouse model 
in which daily treatment of mothers with the antibiotic compound 
vancomycin from gestation day G8 until G17 resulted in increased 
asthma severity in the offspring (Figure 1A). Mothers were treated 
with either 10, 20 or 40 mg vancomycin per kg body weight, cor-
responding to low, medium, and high vancomycin doses in humans, 
and as a prenatal control, mothers received sterile water (Figure 1B). 
Using a novel method adapted from,31 we used a pipet to feed mice 
vancomycin mixed with Ora-Sweet, which is a medically approved 
syrup used to sweeten antibiotics for children.32 In our experience, 
untrained, hand-held mice readily ate the entirety of the antibiotic 
mixture within a 10 second delivery time (Figure 1C). Offspring from 
all groups were subjected to an ovalbumin (OVA) allergic asthma pro-
tocol beginning at weaning (Figure 1A, B).
3.2 | Maternal treatment with a high antibiotic 
concentration increased miscarriages and 
reduced offspring weight
To assess the effect of maternal treatment with antibiotics on preg-
nancy outcome, we recorded litter sizes, miscarriage rates, offspring 
sex and adult offspring weight. Of the term pregnancies, the mean 
litter size was 4.5 pups and no differences were observed in litter 
size or pup sex between groups (Figure 1D). In mice with confirmed 
pregnancy (more than 3.5 grams of weight gained from G0-G13),33 
we observed increased miscarriages, that is, abortion of all pups, with 
increasing antibiotic concentration. Mothers treated with 20 mg/kg 
vancomycin had a 9% miscarriage rate, whereas in mice with 40 mg/
kg the number rose to 30%. Control mothers and those exposed to 
10 mg/kg vancomycin had no observed miscarriages. In addition to 
miscarriage, prenatal exposure to increasing antibiotic concentra-
tions was also associated with decreased offspring weight in a dose-
dependent manner. Seven-week-old allergic offspring from mothers 
treated with 20 mg/kg and 40 mg/kg vancomycin weighed signifi-
cantly less than allergic offspring from control mothers (Figure 1E).
3.3 | Maternal antibiotic treatment during 
pregnancy increased offspring asthma severity in a 
dose-dependent manner
To determine how antibiotic use during pregnancy impacts off-
spring asthma severity, we induced experimental allergic asthma 
in offspring derived from control- and antibiotic-treated moth-
ers. As expected, serum from all allergic offspring contained 
OVA-specific IgE and OVA-specific IgG1, though no differences 
were observed in these antibodies or total IgG concentrations 
Vol. Inf= (ΣPI)×9.395∕(ΣLG+ΣLV)
Nu.G= (ΣLG×100)∕(ΣLG+ΣLnG)
Vol. G= (ΣPG×9.395)∕(ΣLG+ΣLnG)
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between maternal control (MC) and maternal vancomycin (MV) 
allergic offspring groups (Figure 2A). Analysis of allergic off-
spring inflammation revealed increasing asthma severity in 
correspondence with increasing maternal vancomycin concentra-
tions. Histopathological quantification of pulmonary inflamma-
tion and mucous production revealed that allergic offspring from 
F I G U R E  2   Maternal antibiotic treatment during pregnancy results in increased asthma severity in the offspring. A, Serum antibody 
titers from OVA allergic offspring: OVA-specific IgE, OVA-specific IgG1 and Total IgG. B, Allergic offspring lung histology quantification: 
eosinophilic inflammation, goblet cell percentage, goblet mucous volume. C, Allergic offspring lung histology images. Scale bar = 100 µm. D, 
Bronchoalveolar lavage (BAL) cell counts from allergic offspring: leukocytes, eosinophils, macrophages, and lymphocytes. Data information: 
Means ± SEM are shown, control (n = 18), prenatal 10 mg/kg (n = 19), prenatal 20 mg/kg (n = 18), prenatal 40 mg/kg (n = 16). Results 
represent two independently performed experiments. Significance is represented by *P < .05, **P < .01, ***P < .001, one-way ANOVA or 
Kruskal-Wallis test with Dunnett's multiple comparisons test (10, 20, and 40 compared against control)
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mothers treated with 20 or 40 mg/kg vancomycin (henceforth 
referred to as MV20 and MV40 allergic offspring, respectively) 
displayed significantly increased airway and vessel eosinophilic 
inflammatory responses as well as increased goblet cell numbers 
and mucous volume when compared to allergic offspring from 
control mothers (Figure 2B, C).
In addition to tissue inflammation, total leukocyte influx into 
the bronchoalveolar lavage (BAL) fluid was significantly increased in 
MV20 and MV40 allergic offspring; this result was largely due to 
increased numbers of eosinophils and macrophages (Figure 2D). In 
the BAL, increased allergic lung inflammation correlated with signifi-
cantly lower concentrations of 12 of the 23 measured BAL cytokines, 
namely IL-1β, IL-4, IL-5, IL-9 IL-10, IL-12p70, eotaxin, G-CSF, GM-CSF, 
MCP1, MIP-1α and RANTES (Table 1). Finally, correlation analysis 
showed that increasing vancomycin concentration during pregnancy 
correlated with significantly increased asthma severity in the off-
spring (Figure S1A-D). In summary, based on significant increases in 
lung inflammation, mucous production, and BAL cell infiltrates, as 
well as a correlated decrease in BAL cytokines in MV20 and MV40 
allergic offspring, we thereby show that maternal antibiotic treat-
ment during pregnancy was associated with increased severity of 
offspring allergic asthma.
3.4 | Antibiotic treatment during pregnancy 
altered the maternal and offspring intestinal 
microbiomes
To correlate increased MV offspring asthma severity with changes 
in gut microbial communities, we quantified the changing fecal mi-
crobiome composition of mothers and their offspring using qPCR. 
At G17, following antibiotic treatment, we observed a significant in-
crease in total bacterial load in all mothers that were treated with 
vancomycin in comparison to control G17 mothers (Figure 3A). At 
weaning (23 days after the last antibiotic treatment), total bacte-
rial loads of vancomycin-treated mothers returned to control levels; 
however, all MV offspring had significantly increased fecal bacte-
rial numbers, both at weaning and as allergic adults. The increased 
bacterial load in MV mothers corresponded to greatly increased 
numbers (up to Log 4) of bacteria in the Enterobacteriaceae in all 
vancomycin-treated groups (Figure 3B). qPCR additionally revealed 
that microbes in the Bacteroidetes were also increased (Log 2) in G17 
maternal feces in the MV10 and MV20 groups (Figure 3C). Again, 
members of this group returned to control levels in the mothers at 
weaning, whereas they remained elevated in offspring from all MV 
groups, both at weaning and as allergic adults (Figure 3C). Mouse 
TA B L E  1   Bronchoalveolar lavage from allergic offspring displays decreased cytokine concentrations with increasing prenatal antibiotic 
exposure
Concentration (pg/mL)
Maternal control Maternal 10 mg/kg Maternal 20 mg/kg Maternal 40 mg/kg
n = 18 n = 18 n = 13 n = 16
Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM)
IL-1α 7.2 (0.4) 8.5 (0.9) 9.0 (0.8) 9.0 (1.0)
IL-1β 48.0 (4.9) 36.1 (4.0) 22.0 (5.3)** 25.4 (5.6)*
IL-2 164.8 (18.1) 6.4 (0.4) 6.6 (0.4) 6.8 (0.7)
IL-4 165.4 (17.5) 142.9 (16.4) 82.9 (16.9)* 145.0 (4.2)
IL-5 164.8 (18.1) 146.2 (11.4) 103.2 (17.2)* 130.7 (13.4)
IL-6 9.7 (2.9) 10.3 (1.6) 9.7 (1.6) 8.2 (1.4)
IL-9 42.0 (6.0) 20.9 (5.5)* 26.4 (7.8) 9.7 (4.4)***
IL-12p40 52.6 (4.2) 43.4 (2.8) 40.1 (3.8) 44.4 (4.2)
IL-12p70 12.4 (1.0) 11.1 (0.7) 7.7 (0.8)** 9.1 (1.3)*
IL-13 111.1 (13.4) 83.6 (9.3) 81.5 (12.1) 92.2 (9.6)
Eotaxin 161.6 (7.2) 141.0 (7.0) 135.6 (11.2) 113.0 (16.9)**
G-CSF 8.4 (0.8) 7.9 (0.9) 5.3 (0.9)* 5.5 (0.9)*
GM-CSF 10.0 (0.6) 8.5 (0.3) 6.5 (0.6)*** 3.3 (6.5)***
KC 213.2 (27.5) 230.8 (29.1) 240.7 (34.7) 207.3 (26.5)
MCP-1 28.9 (5.9) 16.2 (2.8) 4.7 (3.0)*** 6.1 (2.7)***
MIP-1α 9.8 (0.9) 9.6 (0.6) 5.1 (0.1)*** 7.7 (0.9)
MIP-1β 4.3 (0.4) 3.8 (0.2) 2.4 (0.3)*** 2.6 (0.2)***
RANTES 6.5 (0.4) 5.8 (0.2) 4.7 (0.3)** 5.3 (0.4)*
TNFα 20.9 (1.3) 19.6 (1.0) 17.1 (1.9) 22.6 (4.7)
Note: Data information: Means ± SEM are shown, control (n = 18), prenatal 10 mg/kg (n = 19), prenatal 20 mg/kg (n = 18), prenatal 40 mg/kg (n = 16). 
Results represent two independently performed experiments. Significance is represented by *P < .05, **P < .01, ***P < .001 one-way ANOVA or 
Kruskal-Wallis test with Dunnett's multiple comparisons test (10, 20, and 40 compared against control).
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Intestinal Bacteroides (MIB) followed a similar pattern but with less 
pronounced differences between groups (Figure S2A).
Considering gram-positive bacteria, qPCR analysis revealed an 
expected decrease in the fecal Clostridium leptum group in all vanco-
mycin-treated mothers at G17 (up to Log 4 decrease) (Figure 3D). A 
similar trend was observed in the Clostridium coccoides/Eubacterium 
Rectale group (Figure S2B). Clostridium leptum remained significantly 
decreased in both mothers and offspring at weaning and in the adult 
allergic offspring (Log1) (Figure 3D). Finally, Lactobacillus concentra-
tions did not show any major differences between control and van-
comycin-treated mothers or pups (Figure S2C).
To expand on the qPCR data, we chose the group with the great-
est increase in asthma severity (MV20), to examine the maternal and 
offspring fecal microbiome by 16S amplicon sequencing. 16S am-
plicon analysis confirmed that members of the Enterobacteriaceae 
increased in relative abundance at G17 in MV20 maternal feces 
(Figure 4A). One of the most differentially abundant operational tax-
onomic units (OTUs) at G17 in MV20 maternal feces was identified 
as Escherichia coli, a member of the Enterobacteriaceae (Figure 4B). 
16S amplicon analysis also allowed us to infer the contributions of 
particular taxa to the Bacteroidetes qPCR results. In MV20 mothers 
at G17, OTUs corresponding to unclassified Bacteroidetes had ele-
vated relative abundances (Figure 4C), whereas in MV20 offspring 
at weaning and at adulthood, different OTUs belonging to the genus 
Bacteroides had increased relative abundances (Figure 4D). The gen-
era, Prevotella and Porphyromonas, did not appear to contribute to 
the increase in Bacteroidetes, as the relative abundance of the for-
mer actually decreased in MV20 mothers and offspring at all time 
points measured after vancomycin treatment (Figure 4D); the lat-
ter did not make up a substantial proportion of sequencing reads 
(<0.001%).
16S amplicon analysis of Clostridium confirmed our observations 
in the MV20 groups, with the G17 time point, as well as mothers 
and offspring at weaning, having significantly lower relative abun-
dances of OTUs classified as members of the order, Clostridiales. 
In summary, these data confirm that the increases in total fecal 
bacterial numbers in vancomycin-treated mothers at G17 and in 
their offspring at weaning and adulthood is likely due to a bloom of 
F I G U R E  3   qPCR analysis of the fecal microbiome from mothers and offspring. Broad bacterial clades in the maternal and offspring fecal 
microbiome were quantified in all treatment groups using taxa-specific 16S rRNA qPCR. A, Total eubacterial load, B, γ-proteobacteria—
Enterobacteriaceae, C, Bacteroidetes—Bacteroides, Prevotella, and Porphyromonas, D, Clostridium leptum group. Data information: Medians 
(black bars) are shown, Maternal: control (n = 6), 10 mg/kg, (n = 8), 20 mg/kg (n = 7), 40 mg/kg (n = 6). Offspring: from control mothers 
(n = 18), from 10 mg/kg vancomycin-treated mothers (n = 19), from 20 mg/kg vancomycin-treated mothers (n = 18), from 40 mg/kg 
vancomycin-treated mothers (n = 16). Results represent two independently performed experiments. Significance is represented by *P < .05, 
**P < .01, ***P < .001, one-way ANOVA or Kruskal-Wallis test with Dunnett's multiple comparisons test (10, 20, and 40 compared against 
control)
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gram-negative E coli as well as bacteria in the phylum Bacteroidetes. 
These increases were accompanied by comparable decreases in 
members from the order Clostridiales.
3.5 | SCFAs are significantly decreased in the 
cecum of MV allergic offspring
Due to the associations between the microbiome, SCFA production, 
and asthma susceptibility, we also measured SCFAs in the cecum 
of MC and MV allergic offspring. In both humans16 and mice,18 de-
creased levels of fecal SCFAs are associated with increased asthma 
susceptibility and severity. In agreement with these studies, we 
found that increased asthma severity in MV allergic offspring was 
associated with significant decreases in cecal SCFAs. Correlation 
analyses further indicated that increasing vancomycin dose during 
pregnancy (Figure S3A-D), as well as increasing total bacterial num-
bers at G17 (Figure S4A-D), were correlated with decreased SCFA 
concentrations in the offspring. As shown in Figure 5A and B, all MV 
allergic offspring had significantly decreased concentrations of cecal 
acetate and valerate, whereas cecal propionate was only decreased 
in the MV40 group (Figure 5C). Cecal butyrate was decreased in both 
the MV20 and MV40 allergic offspring groups (Figure 5D), of which 
MV20 displayed the most severe asthma phenotype. Decreased 
F I G U R E  4   16S rRNA amplicon sequencing analysis of the fecal microbiome from MV20 mothers and offspring. Relative abundance 
of A, Enterobacteriaceae, B, Escherichia coli, C, an unclassified species of Bacteroidetes, D, Bacteroides, E, Prevotella, F, Clostridiales. Data 
information: Medians (black bars) are shown. Maternal: control (n = 6), 10 mg/kg, (n = 8), 20 mg/kg (n = 7), 40 mg/kg (n = 6). Offspring: from 
control mothers (n = 18), from 10 mg/kg vancomycin-treated mothers (n = 19), from 20 mg/kg vancomycin-treated mothers (n = 18), from 
40 mg/kg vancomycin-treated mothers (n = 16). Results represent two independently performed experiments. Significance is represented by 
*P < .05, **P < .01, ***P < .001. A Mann-Whitney U test was performed (control vs 20 mg/kg)
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cecal butyrate concentrations in these groups were also associated 
with significantly decreased Clostridium leptum gene numbers in the 
feces (Figure 3D).
4  | DISCUSSION
We have designed the first mouse model in which maternal treat-
ment with antibiotics only during pregnancy resulted in increased 
asthma severity in the offspring. Our model is unique in that the 
offspring were not exposed directly to the antibiotic. Other groups 
have demonstrated that prenatal plus neonatal exposure to anti-
biotics resulted in increased offspring asthma severity; however, 
these models also treated the offspring with antibiotic from birth 
until allergy induction.34,35 Russell et al (2013) tested the effect of 
vancomycin given only during pregnancy on offspring asthma devel-
opment in mice, but found no difference between MV and MC aller-
gic offspring.36 We propose that the difference observed between 
studies reflects the mode of vancomycin delivery. Delivery of medi-
cation individually to mice with a pipet is an excellent alternative to 
delivering antibiotics by gavage or via water bottles. Gavage is very 
stressful for pregnant mice, while water bottle distribution of antibi-
otics is limited by the facts that (a) individual mouse dosage cannot 
be measured precisely and (b) antibiotic may not reach the minimum 
inhibitory concentration due to the small-dose, high-frequency man-
ner of water bottle delivery.37
Maternal vancomycin treatment during pregnancy increased 
offspring asthma severity in a dose-dependent manner. This is in 
line with several human studies that show higher asthma risk in 
children whose mothers were prescribed antibiotics several times 
during pregnancy.3 MV allergic offspring displayed significantly 
augmented inflammation in the lung tissue and BAL. Regarding 
BAL cytokine levels, which are often reported to increase with 
increasing asthma severity, we expected that animals with higher 
inflammation would also display increased type 2 cytokines. To 
our surprise, increased airway inflammation was associated with 
significantly lower concentrations of 12 of the 23 measured BAL 
cytokines. The type 2 cytokines IL-4 and IL-5 were among the cy-
tokines decreased in the MV20 and MV40 allergic offspring; IL-13, 
however, did not show any difference between groups. Since the 
decreased allergic offspring BAL cytokine concentrations were 
correlated with increasing maternal vancomycin concentration, 
this strongly reduces the possibility of random error. Additionally, 
we have also observed this phenomenon using an unrelated prena-
tal risk model in our laboratory (unpublished information). At the 
moment, we unfortunately cannot offer a firm explanation as to 
why decreased cytokine levels were observed. This topic requires 
specifically designed future studies to examine this question in 
further detail.
Maternal vancomycin treatment during pregnancy was associ-
ated with microbial dysbiosis that was passed on to the offspring. 
Both taxa-specific 16S rRNA qPCR and universal bacterial primer 
F I G U R E  5   Short-chain fatty acids 
are decreased in the cecum of allergic 
offspring whose mothers were treated 
with vancomycin during pregnancy. 
Short-chain fatty acid concentrations in 
the cecum of allergic offspring. A, Acetate, 
B, valerate, C, propionate, D, butyrate. 
Data information: Means ± SEM are 
shown, control (n = 18), prenatal 10 mg/
kg (n = 19), prenatal 20 mg/kg (n = 18), 
prenatal 40 mg/kg (n = 16). Results 
represent two independently performed 
experiments. Significance is represented 
by *P < .05, **P < .01, ***P < .001one-
way ANOVA or Kruskal-Wallis test with 
Dunnett's multiple comparisons test (10, 
20, and 40 compared against control)
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16S rRNA amplicon sequencing were used to analyze the intestinal 
microbiota of both mothers and offspring at several different time 
points. The two methods are complementary, with the former quan-
tifying the density of targeted populations and the latter providing 
relative abundances of most bacterial taxa. At G17, maternal vanco-
mycin treatment was associated with substantial (Log 4) increases 
in Enterobacteriaceae and unidentified Bacteroidetes. Given that 
vancomycin mainly targets gram-positive bacteria,38 this bloom of 
bacteria is likely due to the availability of new intestinal ecological 
niches. Accordingly, at G17 we also observed log 4 decreases in ma-
ternal Clostridia. The maternal microbiota is thought to contribute 
directly to the neonatal microbiome composition due to transfer of 
bacteria during birth7 and, in mice, through consumption of maternal 
feces by neonates in early life.39 Our analysis of the fecal microbi-
ota from the offspring supports this notion. Pups and adult allergic 
offspring from vancomycin-treated mothers had an increased bac-
terial load that was contributed to by Enterobacteriaceae as well 
as Bacteroidetes. Additionally, qPCR and amplicon sequencing con-
firmed that Clostridiales was also decreased in offspring at weaning.
In both humans 16 and mice,18 changes to the microbiome are 
associated with decreased levels of fecal SCFAs and increased 
asthma susceptibility. Our study also demonstrated that MV al-
lergic offspring had significantly decreased cecal SCFA concen-
trations compared to their MC allergic counterparts. Further 
analysis showed that both maternal vancomycin concentration 
and maternal total bacterial load at G17 were significantly as-
sociated with decreased SCFA concentrations in allergic off-
spring, with butyrate being the most strongly impacted. Studies 
have revealed the importance of this SCFA in allergic asthma, 
demonstrating that butyrate supplementation during asthma 
sensitization of adult mice resulted in protection against air-
way inflammation.19 Additionally, mice treated with vancomycin 
since birth could be rescued from a severe asthma phenotype by 
supplementation with butyrate during vancomycin treatment.40 
Butyrate acts as an inflammatory regulator, and several studies 
have implicated butyrate in protection against asthma via FoxP3 
induction on regulatory T cells and subsequent suppression of in-
flammatory Th9 cells in the allergic lung.19
4.1 | Conclusion
We have established the first mouse model in which maternal an-
tibiotic treatment during pregnancy increases offspring asthma se-
verity. Increased asthma severity was accompanied by maternal and 
offspring microbial dysbiosis, as well as decreases in offspring cecal 
acetate, butyrate, and valerate concentrations. Our model is ideal 
for mechanistic analysis of how antibiotics given during pregnancy 
can alter offspring immune system development and subsequent 
disease susceptibility. Future analyses will examine SCFA produc-
tion in concert with fetal and neonatal development to better un-
derstand the effects of antibiotic use during pregnancy at critical 
developmental time points.
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